4.6 Article

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Review Oncology

PD-L1 assessment in urothelial carcinoma: a practical approach

Markus Eckstein et al.

ANNALS OF TRANSLATIONAL MEDICINE (2019)

Article Cell Biology

Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma

Viktor H. Koelzer et al.

HISTOPATHOLOGY (2018)

Review Biochemistry & Molecular Biology

Liquid biomarkers in melanoma: detection and discovery

Su Yin Lim et al.

MOLECULAR CANCER (2018)

Article Medicine, General & Internal

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M. M. Eggermont et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Multidisciplinary Sciences

Automated Gleason grading of prostate cancer tissue microarrays via deep learning

Eirini Arvaniti et al.

SCIENTIFIC REPORTS (2018)

Article Medicine, Research & Experimental

Melanoma subtypes demonstrate distinct PD-L1 expression profiles

Genevieve J. Kaunitz et al.

LABORATORY INVESTIGATION (2017)

Article Medicine, General & Internal

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

J. Weber et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Medicine, General & Internal

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

G. V. Long et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Review Oncology

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Sandip Pravin Patel et al.

MOLECULAR CANCER THERAPEUTICS (2015)

Article Medicine, General & Internal

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Multidisciplinary Sciences

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh et al.

NATURE (2014)

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Biochemical Research Methods

Fiji: an open-source platform for biological-image analysis

Johannes Schindelin et al.

NATURE METHODS (2012)

Article Medicine, General & Internal

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L. Topalian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Oncology

New guidelines to evaluate the response to treatment in solid tumors

F Duffaud et al.

BULLETIN DU CANCER (2000)

Article Oncology

New guidelines to evaluate the response to treatment in solid Tumors

P Therasse et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)